[go: up one dir, main page]

PT2433940E - Derivado de espiroimidazolona - Google Patents

Derivado de espiroimidazolona Download PDF

Info

Publication number
PT2433940E
PT2433940E PT107697286T PT10769728T PT2433940E PT 2433940 E PT2433940 E PT 2433940E PT 107697286 T PT107697286 T PT 107697286T PT 10769728 T PT10769728 T PT 10769728T PT 2433940 E PT2433940 E PT 2433940E
Authority
PT
Portugal
Prior art keywords
spiroimidazolone
derivative
spiroimidazolone derivative
Prior art date
Application number
PT107697286T
Other languages
English (en)
Inventor
Toru Esaki
Yoshikazu Nishimura
Yoshiaki Isshiki
Naoki Okamoto
Yoshiyuki Furuta
Akemi Mizutani
Masateru Ohta
Wayne Wen Lai
Tomoya Kotake
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of PT2433940E publication Critical patent/PT2433940E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT107697286T 2009-04-28 2010-04-27 Derivado de espiroimidazolona PT2433940E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2009109256 2009-04-28

Publications (1)

Publication Number Publication Date
PT2433940E true PT2433940E (pt) 2014-12-12

Family

ID=43032174

Family Applications (1)

Application Number Title Priority Date Filing Date
PT107697286T PT2433940E (pt) 2009-04-28 2010-04-27 Derivado de espiroimidazolona

Country Status (12)

Country Link
US (2) US9169254B2 (pt)
EP (1) EP2433940B9 (pt)
JP (1) JP5671453B2 (pt)
CY (1) CY1115744T1 (pt)
DK (1) DK2433940T3 (pt)
ES (1) ES2525353T3 (pt)
HR (1) HRP20141126T1 (pt)
PL (1) PL2433940T3 (pt)
PT (1) PT2433940E (pt)
SI (1) SI2433940T1 (pt)
TW (1) TWI496782B (pt)
WO (1) WO2010126030A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2433940E (pt) 2009-04-28 2014-12-12 Chugai Pharmaceutical Co Ltd Derivado de espiroimidazolona
WO2012047617A1 (en) * 2010-09-28 2012-04-12 Radius Health, Inc. Selective androgen receptor modulators
EP2548864B1 (en) 2011-07-22 2014-02-19 Université Joseph Fourier Novel bis-indolic derivatives, a process for preparing the same and their uses as a drug
CN104854106B (zh) * 2012-12-10 2017-07-04 中外制药株式会社 乙内酰脲衍生物
TWI686392B (zh) * 2014-06-09 2020-03-01 日商中外製藥股份有限公司 含有乙內醯脲衍生物之醫藥組合物
JP6290138B2 (ja) * 2014-06-09 2018-03-07 中外製薬株式会社 ヒダントイン誘導体含有医薬組成物
EP3153166B1 (en) 2014-06-09 2022-08-03 Chugai Seiyaku Kabushiki Kaisha Hydantoin derivative-containing pharmaceutical composition
WO2016172496A1 (en) 2015-04-23 2016-10-27 Constellation Pharmaceuticals, Inc. Lsd1 inhibitors and uses thereof
CN105017252B (zh) * 2015-06-30 2017-04-12 河南师范大学 具有生物活性的1,3,8‑三氮杂螺[4,5]癸烷‑2‑胍‑4‑酮类化合物及其制备方法和应用
SMT202200199T1 (it) 2016-06-22 2022-07-21 Ellipses Pharma Ltd Metodi di trattamento del cancro del seno ar+.
ES2961499T3 (es) 2016-10-26 2024-03-12 Constellation Pharmaceuticals Inc Inhibidores de LSD1 y usos médicos de los mismos
ES2853999T3 (es) * 2016-11-14 2021-09-20 Byondis Bv Proceso para la preparación de alpha, omega-diamino alcanos mono-protegidos
IT201600130729A1 (it) * 2016-12-23 2018-06-23 Lundbeck Pharmaceuticals Italy S P A Processo per la produzione degli intermedi del delmopinolo
CN108003037B (zh) * 2018-01-18 2020-07-24 上海仁实医药科技有限公司 一种n-甲基-5-己烯-1-胺的合成工艺
EP3590927A1 (en) 2018-07-05 2020-01-08 Bayer Animal Health GmbH Novel compounds for controlling arthropods
TW202019416A (zh) 2018-07-30 2020-06-01 日商中外製藥股份有限公司 乙內醯脲衍生物的固體分散體
EP4225304B1 (en) * 2020-10-12 2025-12-17 The Regents of The University of Michigan Synthesis of egfr modulators
CN112142634A (zh) * 2020-11-02 2020-12-29 广州市科虎生物技术研究开发中心 一种（2-羧乙基）二甲基氯化锍的制备方法
CN112574226A (zh) * 2020-12-15 2021-03-30 海门华祥医药科技有限公司 5,6-亚甲基二氧基吲哚的制备方法
CN114409569A (zh) * 2021-12-23 2022-04-29 江苏长青农化股份有限公司 一种手性稻瘟酰胺的制备方法
WO2024143501A1 (ja) 2022-12-28 2024-07-04 中外製薬株式会社 分散対象物質を含む固体分散体、それを含む医薬組成物及びそれらの製造方法
CN116969831B (zh) * 2023-08-01 2025-09-23 菏泽皓元医药科技有限公司 一种莫奈太尔的中间体及其制备方法
CN117263810A (zh) * 2023-09-19 2023-12-22 上海凌凯医药科技有限公司 还原硝基苯制备苯胺类化合物以及选择性碘代苯胺类化合物的方法
WO2025226892A1 (en) * 2024-04-24 2025-10-30 Septerna, Inc. Spirocycle-containing diaminomethylene pyrimidine-2,4,6-trione agonists of parathyroid hormone 1 and incretin receptors
WO2025226895A1 (en) * 2024-04-24 2025-10-30 Septerna, Inc. Agonists of parathyroid hormone 1 and incretin receptors comprising substituted or modified diaminomethylene pyrimidine-2,4,6-triones

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1135470A (ja) 1997-07-23 1999-02-09 Teijin Ltd ビタミンｄ３誘導体を含有する副甲状腺ホルモン産生促進剤
TR200101644T2 (tr) 1998-12-11 2001-11-21 F.Hoffmann-La Roche Ag TNF-ALFA önleyicileri olarak siklik hidrazin türevleri.
AU2001284412A1 (en) 2000-08-30 2002-03-13 Teijin Limited Parathyroid hormone production inhibitors containing vitamin D3 derivatives
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
AR038658A1 (es) 2001-06-15 2005-01-26 Novartis Ag Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
EP1713782A4 (en) 2004-02-11 2009-11-11 Smithkline Beecham Corp PTH AGONISTS
WO2005077959A1 (en) 2004-02-11 2005-08-25 Smithkline Beecham Corporation Pth agonists
JP2008515895A (ja) 2004-10-07 2008-05-15 メルク エンド カムパニー インコーポレーテッド Ｃｇｒｐ受容体拮抗薬
WO2007135417A1 (en) 2006-05-19 2007-11-29 James Black Foundation Benzotriazepinone derivatives
AR061522A1 (es) 2006-06-20 2008-09-03 Wyeth Corp Derivados de 4-oxo-1, 3, 8-triaza[4.5]decanos como inhibidores del canal de potasio kv1.5, una composicion que los comprende y su empleo en el tratamiento de afecciones cardiacas.
JP2010529069A (ja) 2007-06-07 2010-08-26 エフ．ホフマン−ラ ロシュ アーゲー Ｎｋ３アンタゴニストとしてのプロリンアミド誘導体
KR101578235B1 (ko) * 2007-12-10 2015-12-16 노파르티스 아게 유기 화합물
US7981904B2 (en) * 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
US8513193B2 (en) 2008-10-13 2013-08-20 University Of Rochester Protecting and repairing cartilage and musculoskeletal soft tissues
PT2433940E (pt) 2009-04-28 2014-12-12 Chugai Pharmaceutical Co Ltd Derivado de espiroimidazolona
CN104854106B (zh) 2012-12-10 2017-07-04 中外制药株式会社 乙内酰脲衍生物

Also Published As

Publication number Publication date
JP5671453B2 (ja) 2015-02-18
US20160016956A1 (en) 2016-01-21
JPWO2010126030A1 (ja) 2012-11-01
PL2433940T3 (pl) 2015-03-31
HRP20141126T1 (hr) 2015-01-30
TWI496782B (zh) 2015-08-21
WO2010126030A1 (ja) 2010-11-04
US20120270838A1 (en) 2012-10-25
ES2525353T3 (es) 2014-12-22
EP2433940B1 (en) 2014-09-24
DK2433940T3 (en) 2015-01-12
EP2433940A4 (en) 2012-10-10
CY1115744T1 (el) 2017-01-25
US9169254B2 (en) 2015-10-27
US9487517B2 (en) 2016-11-08
EP2433940B9 (en) 2015-10-28
TW201103938A (en) 2011-02-01
EP2433940A1 (en) 2012-03-28
SI2433940T1 (sl) 2015-01-30

Similar Documents

Publication Publication Date Title
EP2420493A4 (en) HALOALKYLSULFONANILIDE DERIVATIVES
EP2412708A4 (en) SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE
EP2514747A4 (en) SUBSTITUTED AMINOTHIAZINE DERIVATIVE
PT2433940E (pt) Derivado de espiroimidazolona
IL220616A0 (en) Novel 3 - hydroxy - 5 - arylisothiazole derivative
ZA201203205B (en) Benzimidazole-imidazole derivatives
IL217956A0 (en) N1-sulfonyl-5-fluoropyrimidinone derivatives
IL217953A0 (en) 5-fluoropyrimidinone derivatives
EP2495238A4 (en) NEW 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE
PL2397480T3 (pl) Pochodna diazepinodionu
IL216007A0 (en) Isoxazole-pyridine derivatives
IL215109A0 (en) Isoxazole-pyridazine derivatives
ZA201106855B (en) Oxasiazole derivatives
IL214941A0 (en) Isoxazole-pyrazole derivatives
IL217952A0 (en) N1-acyl-5-fluoropyrimidinone derivatives
ZA201104991B (en) Deoxyactagardine derivatives
ZA201202899B (en) 5-hydroxypyrimidine-4-carboxamide derivative
ZA201109370B (en) Pyrazinooxazepine derivatives
EP2476682A4 (en) 8-oxodihydropurine DERIVATIVE
ZA201104279B (en) Tetrahydronaphthalen-2-ol derivatives
GB0912499D0 (en) Indopyl-pyridone derivatives